Clinical Trial Update: Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial exploring adding CBM588 to pembrolizumab for renal cell carcinoma after surgery; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• CBM588
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING